Panexin NTS   Panexin NTS is a ready-to-use, chemically defined serum substitute for the cultivation of suspension cells under serum-free conditions. Panexin NTS is developed with a unique technology and contains a special 3-dimensional substance release system (3D-SRS) for an optimal support of cells with nutrients and growth stimulants. The sterile solution is added to the culture medium in a final concentration of 10%. It supports the growth of many cell types in an optimum manner.   Description Size Product number Datasheet Comparison document Panexin NTS 50 ml100 ml500 ml P04-95080P04-95800P04-95850 Panexin NTSPharma Grade 50 ml100 ml500 ml P04-95080PP04-95800PP04-95850P      Composition Panexin NTS contains purified proteins, lipids, salts, amino acids, trace elements, and hormones in an optimized formulation and a new 3-dimensional substance release system (3D-SRS). Panexin NTS contains no growth factors, undefined hydrolysates or peptones. Panexin NTS Pharma Grade is free of any animal-derived components. Customized formulations (e.g. without hormones and insulin) on request.  Suitability Panexin NTS is suitable for the cultivation of a variety of non-adherent suspension cells under serum-free conditions. Further informations can be found in the datasheet and in the comparison document.  Special advantages Panexin NTS can be used for many cell lines to replace FBS. Due to specially selected and pretested raw materials Panexin NTS batches are very homogeneous. Therefore the complex batch testing known from FBS can be omitted with the use of Panexin NTS. Panexin NTS is completely chemically defined and contains no growth factors, undefined peptones or hydrolysates. Due to this special formulation the interpretation of results from studies on effects of individually added growth factors is easier and more reliable in serum-free conditions. For cell lines which require specific growth factors these should be added in a concentration as previously used.  References by cell lines Panexin products are chemically defined serum substitutes, which have been successfully applied for a wide range of cell cultures. As demonstrated in the references, Panexin can be generally used to avoid the undesired and non-specific components in serum (exosom, growth factors and hormones etc), not only for defined cell proliferation and differentiation, but also to allow more accurate analytics and to increase the sensitivity of the procedure for potential cell-based diagnostic applications. More importantly, the users are disburdened from the necessary extensive testing work and ethic concerns behind the serum products. Compared to various commercial cell-specific serum-free, but undefined full media, Panexin offers huge potential to develop users’ own defined media.  Tumor Cells Human pancreatic adenocarcinoma cells• Gamper et al., Cell Biology International Volume 40, Issue 10, Pages 1050–106, 2016. http://onlinelibrary.wiley.com/doi/10.1002/cbin.10645/full • Freud et al., Preprints 2016, 2016100056 www.preprints.org/manuscript/201610.0056/v1/download • Schlingensiepen et al., Cancer Science Volume 102, Issue 6 June 2011 Pages 1193–1200 http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2011.01917.x/full • HouHou et al., Patent US20110171213 A1Human prostate cancer cells • Lisa Rauschenberger, Dissertation „Strukturelle und funktionelle Charakterisierung von Exosomen aus Prostatakarzinomzellen“, 2016. http://d-nb.info/111106475X/34 • Rauschenberger et al., Prostate. 2016 Mar;76(4):409-24 https://www.ncbi.nlm.nih.gov/pubmed/26643154 • Stope et al., Anticancer Res. 2013 Nov;33(11):4921-6 https://www.ncbi.nlm.nih.gov/pubmed/24222130 Human liposarcoma • Harati et al., Int J Mol Med. 2016 Jun; 37(6): 1535–1541. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867885/pdf/ijmm-37-06-1535.pdf Tumor (adenocarcinoma) primary fibroblasts • Castoldi, Dissertation “Generation and characterization of multi-specific antibodies for therapeutic applications in oncology”, 2014. https://edoc.ub.uni-muenchen.de/16625/1/Castoldi_Raffaella.pdf Human hepatoblastoma cells • S Beckers, Dissertation “High throughput toxicity, physiological and metabolic studies for the characterization of hepatocytes and human embryonic stem cell derived hepatocyte-like cells.”, 2011http://scidok.sulb.uni-saarland.de/volltexte/2011/3665/pdf/Dissertation_Simone_Beckers_23.03_neu.pdf Human breast cancer cell • Peter et al., Journal of Biomolecular Techniques 18:287–297 © 2007 ABRF https://www.researchgate.net/profile/Jochen_Peter/publication/5682413_Enrichment_and_detection_of_molecules_secreted_by_tumor_cells_using_magnetic_reversed-phase_particles_and_LC-MALDI-TOF-MS/links/5460abd40cf2c1a63bfeb17e.pdf  Other Human Cells Rheumatoid arthritis synovial fibroblasts • Zimmermann-Geller et al., The Journal of Immunology October 1, 2016 vol. 197 no. 7 2589-2597. http://www.jimmunol.org/content/197/7/2589.short Coculture: Human liposarcoma cells and tumor-associated fibroblasts • Harati et al., Int J Mol Med. 2016 Jun; 37(6): 1535–1541. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867885/pdf/ijmm-37-06-1535.pdf. Coculture: MRC5 and tumor-associated fibroblasts • Majety et al., PLOS ONE | DOI:10.1371/journal.pone.0127948 June 8, 2015 http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0127948&type=printable. Coculture: SZ95 sebocytes and normal human fibroblasts • Nikolakis et al., https://www.ncbi.nlm.nih.gov/pubmed/25828468 • http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0127948&type=printable. Coculture: H596 and normal and tumor (adenocarcinoma) primary fibroblasts • Castoldi, Dissertation “Generation and characterization of multi-specific antibodies for therapeutic applications in oncology”, 2014 https://edoc.ub.uni-muenchen.de/16625/1/Castoldi_Raffaella.pdf Human corneal epithelial cells • Hahne et al., Int J Pharm. 2011 Sep 15;416(1):268-79 https://www.ncbi.nlm.nih.gov/pubmed/21771646 Human myometrial microvascular endothelial cells • Dietrich et al., Fertil Steril. 2011 Mar 15;95(4):1247-55.e1-2 https://www.ncbi.nlm.nih.gov/pubmed/21130428  Stem Cells rMSC • Puts et al., Ultrasound in Medicine & Biology, Volume 42, Issue 12, December 2016, Pages 2965–2974. http://ieeexplore.ieee.org/document/7317777/ • Puts et al., Ultrasonics Symposium (IUS), 2014 IEEE International,3-6 Sept. 2014 http://ieeexplore.ieee.org/document/6932303/ hMSC • Ichikawa et al., Cell Biol Int. 2010 Apr 27;34(6):615-20 https://www.ncbi.nlm.nih.gov/pubmed/20218971 Hematopoietic cells • Ridder et al., PLoS Biol. 2014 Jun; 12(6): e1001874. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043485/  Other Cell Lines Bone marrow derived macrophages • Stolt et al., J Immunol. 2016 Aug 1;197(3):834-46. http://www.jimmunol.org/content/197/3/834.short • Hommes et al., Am J Respir Cell Mol Biol. 2015 Nov;53(5):647-55 http://www.atsjournals.org/doi/pdf/10.1165/rcmb.2014-0485OC • Hof et al., Infect Immun. 2014 May; 82(5): 2006–2015 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3993457/ • Depke et al., Journal of Proteomics Volume 103, 30 May 2014, Pages 72–86 http://www.sciencedirect.com/science/article/pii/S1874391914001493 • Schramm et al., Eur. J. Immunol. 2014. 44: 728–741. http://onlinelibrary.wiley.com/doi/10.1002/eji.201343940/full • Bast et al., LoS Pathog 10(3): e1003986. doi:10.1371/journal.ppat.1003986. http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003986 • Koh et al., PLoS Negl Trop Dis. 2013 Oct; 7(10): e2500 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798430/ • Farinacci et al., Vaccine. 2012 Dec 14;30(52):7608-14 https://www.ncbi.nlm.nih.gov/pubmed/23088886 • Erttmann et al., Free Radic Biol Med. 2011 Aug 1;51(3):626-40 http://www.sciencedirect.com/science/article/pii/S0891584911003248 • Norville et al., Microbiology. 2011 Sep;157(Pt 9):2629-38 https://www.ncbi.nlm.nih.gov/pubmed/21680634 • Breitbach et al., BMC Immunol. 2011; 12: 20 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072354/ • Bast et al., Toxicol In Vitro. 2010 Mar;24(2):686-94. https://www.ncbi.nlm.nih.gov/pubmed/20869433 • Eske et al., J Immunol Methods. 2009 Mar 15;342(1-2):13-9. https://www.ncbi.nlm.nih.gov/pubmed/19133267 • Breitbach et al., Infect Immun. 2009 Apr; 77(4): 1589–1595 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663179/ • Traeger et al., Infect Immun. 2008 Nov; 76(11): 5285–5293 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2573314/ HEK • Lisa Rauschenberger, Dissertation „Strukturelle und funktionelle Charakterisierung von Exosomen aus Prostatakarzinomzellen“, 2016. http://d-nb.info/111106475X/34 • Into et al., Mol Cell Biol. 2008 Feb; 28(4): 1338–1347. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2258749/ And many more!!!